Impact of Four Rounds of Mass Drug Administration with Dihydroartemisinin-Piperaquine Implemented in Southern Province, Zambia

Thomas P Eisele, Adam Bennett, Kafula Silumbe, Timothy P Finn, Travis R Porter, Victor Chalwe, Busiku Hamainza, Hawela Moonga, Emmanuel Kooma, Elizabeth Chizema Kawesha, Mulakwa Kamuliwo, Joshua O Yukich, Joseph Keating, Kammerle Schneider, Ruben O Conner, Duncan Earle, Laurence Slutsker, Richard W Steketee, John M Miller, Thomas P Eisele, Adam Bennett, Kafula Silumbe, Timothy P Finn, Travis R Porter, Victor Chalwe, Busiku Hamainza, Hawela Moonga, Emmanuel Kooma, Elizabeth Chizema Kawesha, Mulakwa Kamuliwo, Joshua O Yukich, Joseph Keating, Kammerle Schneider, Ruben O Conner, Duncan Earle, Laurence Slutsker, Richard W Steketee, John M Miller

Abstract

Over the past decade, Zambia has made substantial progress against malaria and has recently set the ambitious goal of eliminating by 2021. In the context of very high vector control and improved access to malaria diagnosis and treatment in Southern Province, we implemented a community-randomized controlled trial to assess the impact of four rounds of community-wide mass drug administration (MDA) and household-level MDA (focal MDA) with dihydroartemisinin-piperaquine (DHAP) implemented between December 2014 and February 2016. The mass treatment campaigns achieved relatively good household coverage (63-79%), were widely accepted by the community (ranging from 87% to 94%), and achieved very high adherence to the DHAP regimen (81-96%). Significant declines in all malaria study end points were observed, irrespective of the exposure group, with the overall parasite prevalence during the peak transmission season declining by 87.2% from 31.3% at baseline to 4.0% in 2016 at the end of the trial. Children in areas of lower transmission (< 10% prevalence at baseline) that received four MDA rounds had a 72% (95% CI = 12-91%) reduction in malaria parasite prevalence as compared with those with the standard of care without any mass treatment. Mass drug administration consistently had the largest short-term effect size across study end points in areas of lower transmission following the first two MDA rounds. In the context of achieving very high vector control coverage and improved access to diagnosis and treatment for malaria, our results suggest that MDA should be considered for implementation in African settings for rapidly reducing malaria outcomes in lower transmission settings.

Conflict of interest statement

Disclosures: The funding source had no role in the conduct, analysis, or interpretation of results of the study. All authors had full access to all the data in the study.

Figures

Figure 1.
Figure 1.
Map of 60 health facility catchment areas included in the mass treatment trial.
Figure 2.
Figure 2.
Trial time line of major activities. This figure appears in color at www.ajtmh.org.
Figure 3.
Figure 3.
Total monthly rainfall, 2011–2016. This figure appears in color at www.ajtmh.org.
Figure 4.
Figure 4.
Spatial distribution of malaria parasite prevalence during peak transmission (April–May) in 2014–2016, from household surveys, Southern Province, Zambia.

References

    1. Zambia Ministry of Health , 2015. Zambia National Malaria Indicator Survey 2015. Lusaka, Zambia: Zambia Ministry of Health.
    1. Zambia Ministry of Health , 2017. NMEC, ed. National Malaria Elimination Strategic Plan 2017–2021: A Strategy to Move from Accelerated Burden Reduction to Malaria Elimination in Zambia (Brief). Lusaka, Zambia: Zambia Ministry of Health.
    1. Eisele TP, et al. 2016. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis 214: 1831–1839.
    1. Eisele TP, et al. 2015. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials 16: 347.
    1. Larsen DA, Bennett A, Silumbe K, Hamainza B, Yukich JO, Keating J, Littrell M, Miller JM, Steketee RW, Eisele TP, 2015. Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design. Am J Trop Med Hyg 92: 913–921.
    1. Wei LJ, Lachin JM, 1988. Properties of the urn randomization in clinical trials. Control Clin Trials 9: 345–364.
    1. Zambia Ministry of Health , 2014. Guidelines on Diagnosis and Treatment of Malaria in Zambia, 4th Edition Lusaka, Zambia: Zambia Ministry of Health.
    1. Silumbe K, et al. 2020. Assessment of the acceptability of testing and treatment during mass drug administration trial for malaria in Zambia using mixed methods. Am J Trop Med Hyg 103 (Suppl 2): 28–36.
    1. Finn TP, et al. 2020. Treatment coverage estimation for mass drug administration for malaria with dihydroartemisinin-piperaquine in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 19–27.
    1. Finn TP, et al. 2020. Adherence to mass drug administration with dihydroartemisinin-piperaquine and Plasmodium falciparum clearance in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 37–45.
    1. Hayes RJ, Bennett S, 1999. Simple sample size calculation for cluster-randomized trials. Int J Epidemiol 28: 319–326.
    1. Bennett A, et al. 2020. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 54–65.
    1. Chalwe V, Silumbe K, Finn TP, Hamainza B, Porter T, Kamuliwo M, Kawesha EC, Miller JM, Steketee RW, Eisele TP, 2017. Adverse event reporting from malaria mass drug administration rounds conducted in southern Zambia. Am J Trop Med Hyg 95: 487.
    1. von Seidlein L, et al. 2019. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in southeast Asia: a cluster randomised trial. PLoS Med 16: e1002745.
    1. Chanda E, Chanda J, Kandyata A, Phiri FN, Muzia L, Haque U, Baboo KS, 2013. Efficacy of ACTELLIC 300 CS, pirimiphos methyl, for indoor residual spraying in areas of high vector resistance to pyrethroids and carbamates in Zambia. J Med Entomol 50: 1275–1281.
    1. Choi KS, et al. 2014. Insecticide resistance and role in malaria transmission of Anopheles funestus populations from Zambia and Zimbabwe. Parasit Vectors 7: 464.
    1. Bennett A, et al. 2017. Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003–2015: a modelling study using data from national surveys. Lancet Glob Health 5: e418–e427.
    1. Lengeler C, 2004. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004: CD000363.
    1. Pluess B, Tanser FC, Lengeler C, Sharp BL, 2010. Indoor residual spraying for preventing malaria. Cochrane Database Syst Rev 4: CD006657.
    1. Gimnig JE, et al. 2003. Impact of permethrin-treated bed nets on entomologic indices in an area of intense year-round malaria transmission. Am J Trop Med Hyg 68: 16–22.
    1. Bousema JT, et al. 2006. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 193: 1151–1159.
    1. Drakeley CJ, Jawara M, Targett GA, Walraven G, Obisike U, Coleman R, Pinder M, Sutherland CJ, 2004. Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop Med Int Health 9: 53–61.
    1. Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, Coleman R, Pinder M, Walraven G, Targett GA, 2005. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med 2: e92.
    1. Griffin JT, Ferguson NM, Ghani AC, 2014. Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat Commun 5: 3136.
    1. Okell LC, et al. 2014. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Commun 5: 5606.
    1. Yukich J, Briët O, Bretscher MT, Bennett A, Lemma S, Berhane Y, 2012. Estimating Plasmodium falciparum transmission rates in low-endemic settings using a combination of community prevalence and health facility data. PLoS One 7: e42861.
    1. Elliott RC, Smith DL, Echodu D, 2018. Medical and entomological malarial interventions, a comparison and synergy of two control measures using a Ross/MacDonald model variant and openmalaria simulation. Math Biosci 300: 187–200.
    1. Hawley WA, et al. 2003. Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya. Am J Trop Med Hyg 68: 121–127.
    1. Parker DM, et al. 2019. Potential herd protection against Plasmodium falciparum infections conferred by mass antimalarial drug administrations. Elife 8: e41023.
    1. Brady OJ, et al. 2017. Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Glob Health 5: e680–e687.
    1. Eisele TP, et al. 2020. Impact of four rounds of mass drug administration with dihydroartemisinin-piperaquine implemented in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 7–18.
    1. Porter T, et al. 2017. Assessing associations between recent travel and malaria parasite prevalence during a mass drug administration campaign in southern Zambia. Am J Trop Med Hyg 95: 282.
    1. Keating J, Miller J, Bennett A, Moonga H, Eisele T, 2009. Plasmodium falciparum parasite infection prevalence from a household survey in Zambia using microscopy and a rapid diagnostic test: implications for monitoring and evaluation. Acta Trop 112: 277–282.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa